This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

9 Stocks Hit 52-Week Highs: WMB, AEO, T, CRUS, TSM, AZO, MJN, WPI, RTN

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player


"We are upgrading AZO to Overweight for the following reasons: (1) AZO's accelerated investment into its commercial initiative provides a baseline 3% comp for the medium term (any DIY gain is gravy on top); (2) the company's cost discipline and commitment to maintain leverage to drive the buyback enhances the stock/earnings revision risk-reward (even if 'only a 3 comp'); (3) given these factors we believe valuation remains attractive (relatively and absolutely); and (4) unfavorable discretionary retail stock seasonality is looming and we favor adding exposure to a defensive GARP stock with idiosyncratic topline opportunities and secular (albeit more modest than prior) tailwinds," JPMorgan analysts wrote in a report Tuesday.

Shares of AutoZone hit a 52-week high Thursday of $395.12. The stock's 52-week low of $266.25 was set on Aug. 8.

AutoZone has a forward P/E of 14.33; the average for specialty retailers is 16.13. For comparison, O'Reilly Automotive (ORLY) has a higher forward P/E of 19.38.

Twelve of the 22 analysts who cover AutoZone rated it buy; 10 analysts gave the stock a hold rating.

TheStreet Ratings gives AutoZone a B- grade with a buy rating and $498.75 price target. The stock has risen 19.86% year to date.

Watson Pharmaceuticals

The drug company acquired Swiss generic drug company Actavis on Wednesday for about $5.6 billion.

"We are raising our sales and EPS estimates as well as our price target for WPI shares following the company's announced acquisition of Actavis for $5.6bn with an additional 5.5mm WPI share earn-out," JPMorgan analysts wrote in a report Thursday. "In our view, the Actavis acquisition represents a transformational move for Watson that will solidify the company's US business and significantly propel its international presence. The potential accretion from the deal appears well above our initial estimates (over 30% accretive to 2013 [earnings per share]), Actavis' diversification is greater than we had anticipated and the combined entity offers a number of potential levers for further EPS upside/growth. Along these lines, we are reiterating our [overweight] rating on WPI shares and see the potential for significant further upside from current levels."

Shares of Watson Pharmaceuticals hit a 52-week high of $75.95 on Thursday. The stock's 52-week low of $55 was set on Jan. 24.

Watson Pharmaceuticals' forward P/E is 11.2; the average for pharmaceutical companies is 22.56. For comparison, Perrigo (PRGO) has a higher forward P/E of 19.27.

Seventeen of the 24 analysts who cover Watson Pharmaceuticals rated it buy; seven analysts gave the stock a hold rating.

TheStreet Ratings gives Watson Pharmaceuticals an A grade with a buy rating and $82.18 price target. The stock has risen 24.38% year to date.

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

-- Written by Alexandra Zendrian

>To contact the writer of this article, click here: Alexandra Zendrian

>To submit a news tip, send an email to:

>To follow the writer on Twitter, go to Alexandra Zendrian.
5 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
WPI $85.73 0.00%
AEO $14.31 0.00%
RTN $126.35 0.00%
T $38.82 0.00%
TSM $23.59 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs